Physician profile
Anthony E Madrid
NPI 1134154313
$6,390.23
in general payments reported to CMS, 2019-2025
32 companies · $963 in 2025
The $963 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $996 · 2020: $876 · 2021: $584 · 2022: $727 · 2023: $794 · 2024: $1,450 · 2025: $963.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,117 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $62.50 · Education: $27.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,116.64 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $62.50 |
| Education | $27.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $1,103.28 | 2019-2025 | Entyvio, Eohilia |
| Abbvie INC. | $673.96 | 2019-2025 | |
| Gilead Sciences, INC. | $496.82 | 2019-2025 | |
| Janssen Biotech, INC. | $417.90 | 2019-2025 | Stelara, Tremfya, Simponi |
| Ipsen Biopharmaceuticals, INC | $396.47 | 2024-2025 | Iqirvo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $389.34 | 2019-2024 | Xifaxan, Trulance |
| Pfizer INC. | $317.78 | 2019-2025 | |
| Medtronic, INC. | $289.53 | 2023-2024 | Gi Genius |
| Braintree Laboratories, INC. | $234.45 | 2019-2025 | Suflave, Sutab |
| Allergan, INC. | $232.59 | 2020 | |
| Genzyme Corporation | $229.12 | 2022-2024 | |
| Celltrion USA INC. | $197.98 | 2024-2025 | Vegzelma, Zymfentra |
| Redhill Biopharma INC. | $180.31 | 2020-2022 | |
| Phathom Pharmaceuticals, INC. | $176.57 | 2025 | Voquezna |
| Celgene Corporation | $169.82 | 2021-2024 | Zeposia |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $152.20 | 2019-2023 | Linx Reflux Management System |
| Qol Medical, LLC | $136.74 | 2019-2024 | Sucraid |
| Merck Sharp & Dohme LLC | $87.65 | 2019-2024 | Dificid |
| Boston Scientific Corporation | $69.95 | 2025 | Spyglass |
| Regeneron Healthcare Solutions, INC. | $66.94 | 2023-2024 | Dupixent |
| Aimmune Therapeutics, INC. | $62.50 | 2023 | |
| Lilly USA, LLC | $50.74 | 2024-2025 | Omvoh |
| Conmed Corporation | $41.20 | 2025 | Conmed Generators, Conmed Biliary |
| Capsovision, INC. | $40.62 | 2023-2024 | Capsocam Plus |
| Daiichi Sankyo INC. | $29.25 | 2019-2021 | |
| Madrigal Pharmaceuticals | $26.73 | 2025 | Rezdiffra |
| Shionogi INC | $26.68 | 2019 | |
| Echosens North America, INC. | $24.29 | 2024 | Fibroscan |
| E.R. Squibb & Sons, L.L.C. | $20.99 | 2022 | |
| Ambu INC. | $19.02 | 2020 | |
| Ucb, INC. | $17.96 | 2019 | |
| Intercept Pharmaceuticals, INC. | $10.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Madrid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.